In our study, immunohistochemistry in 151 cases of ratified BP-NETs demonstrated that FOXM1 as single marker was strongly upregulated in SCLC samples compared to the better-differentiated carcinoid tumors controls. This evidence concerns the gene FOXM1 and carcinoid tumor.